JP2012517478A5 - - Google Patents

Download PDF

Info

Publication number
JP2012517478A5
JP2012517478A5 JP2011550243A JP2011550243A JP2012517478A5 JP 2012517478 A5 JP2012517478 A5 JP 2012517478A5 JP 2011550243 A JP2011550243 A JP 2011550243A JP 2011550243 A JP2011550243 A JP 2011550243A JP 2012517478 A5 JP2012517478 A5 JP 2012517478A5
Authority
JP
Japan
Prior art keywords
use according
patients
hcv rna
weeks
rna levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011550243A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012517478A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/023978 external-priority patent/WO2010093843A2/en
Publication of JP2012517478A publication Critical patent/JP2012517478A/ja
Publication of JP2012517478A5 publication Critical patent/JP2012517478A5/ja
Pending legal-status Critical Current

Links

JP2011550243A 2009-02-12 2010-02-12 ペグ化インターフェロン、リバビリンおよびテラプレビルを含む、ｈｃｖ組合せ治療剤 Pending JP2012517478A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US15212009P 2009-02-12 2009-02-12
US61/152,120 2009-02-12
US17165409P 2009-04-22 2009-04-22
US61/171,654 2009-04-22
US25668609P 2009-10-30 2009-10-30
US61/256,686 2009-10-30
PCT/US2010/023978 WO2010093843A2 (en) 2009-02-12 2010-02-12 Hcv combination therapies

Publications (2)

Publication Number Publication Date
JP2012517478A JP2012517478A (ja) 2012-08-02
JP2012517478A5 true JP2012517478A5 (https=) 2013-03-28

Family

ID=42315464

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011550243A Pending JP2012517478A (ja) 2009-02-12 2010-02-12 ペグ化インターフェロン、リバビリンおよびテラプレビルを含む、ｈｃｖ組合せ治療剤

Country Status (4)

Country Link
US (1) US20120039850A1 (https=)
EP (1) EP2396028A2 (https=)
JP (1) JP2012517478A (https=)
WO (1) WO2010093843A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
CN107898791A (zh) 2010-06-03 2018-04-13 药品循环有限责任公司 布鲁顿酪氨酸激酶(btk)抑制剂的应用
WO2012109646A1 (en) 2011-02-11 2012-08-16 Vertex Pharmaceuticals Incorporated Treatment of hcv in hiv infection patients
DE112012002748T5 (de) 2011-10-21 2014-07-31 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
SE1450131A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US20130195797A1 (en) * 2012-01-31 2013-08-01 Vertex Pharmaceuticals Incorporated High potency formulations of vx-950
WO2013168179A2 (en) * 2012-04-03 2013-11-14 Rubicon Research Private Limited Controlled release pharmaceutical formulations of antiviral agents
CN104704129A (zh) 2012-07-24 2015-06-10 药品循环公司 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
SG11201503459SA (en) 2012-11-02 2015-06-29 Pharmacyclics Inc Tec family kinase inhibitor adjuvant therapy
WO2015143400A1 (en) 2014-03-20 2015-09-24 Pharmacyclics, Inc. Phospholipase c gamma 2 and resistance associated mutations
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1302468B1 (en) 1992-12-29 2008-12-17 Abbott Laboratories Processes and intermediates for manufacturing retroviral protease inhibiting compounds
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
CA2252465C (en) 1996-04-23 2007-07-03 Vertex Pharmaceuticals Incorporated Urea derivatives as inhibitors of impdh enzyme
DK0966465T3 (da) 1997-03-14 2003-10-20 Vertex Pharma Inhibitorer af IMPDH-enzymer
US20040058982A1 (en) 1999-02-17 2004-03-25 Bioavailability System, Llc Pharmaceutical compositions
CA2367017C (en) 1999-03-19 2009-05-26 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
AP2001002290A0 (en) 1999-04-07 2001-12-31 Pfizer Prod Inc Use of CYP2D6 inhibitors in combination therapies.
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
WO2002057425A2 (en) 2001-01-22 2002-07-25 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
CA2369711A1 (en) 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis c virus
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
CA2369970A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
JP2006507235A (ja) 2002-08-01 2006-03-02 フアーマセツト・インコーポレイテツド フラビウイルス科ウイルス感染治療のためのビシクロ［４．２．１］ノナン系を有する化合物
CA2413705A1 (en) 2002-12-06 2004-06-06 Raul Altman Use of meloxicam in combination with an antiplatelet agent for treatment of acute coronary syndrome and related conditions
US7098231B2 (en) 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
BRPI0407587A (pt) 2003-02-18 2006-02-14 Pfizer inibidores do vìrus da hepatite c, composições e tratamentos que os utilizam
WO2004101605A1 (en) 2003-03-05 2004-11-25 Boehringer Ingelheim International Gmbh Hepatitis c inhibiting compounds
DE602004029866D1 (de) 2003-03-05 2010-12-16 Boehringer Ingelheim Pharma Peptidanaloga mit inhibitorischer wirkung auf hepatitis c
AU2004240704B9 (en) 2003-05-21 2009-10-22 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor compounds
WO2005018330A1 (en) 2003-08-18 2005-03-03 Pharmasset, Inc. Dosing regimen for flaviviridae therapy
US6933760B2 (en) 2003-09-19 2005-08-23 Intel Corporation Reference voltage generator for hysteresis circuit
RS20060197A (sr) 2003-09-22 2008-09-29 Boehringer Ingelheim International Gmbh., Makrociklični peptidi koji su aktivni protiv hepatitisa c virusa
AR045870A1 (es) * 2003-10-11 2005-11-16 Vertex Pharma Terapia de combinacion para la infeccion de virus de hepatitis c
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP1730167B1 (en) 2004-01-21 2011-01-12 Boehringer Ingelheim International GmbH Macrocyclic peptides active against the hepatitis c virus
US20050187192A1 (en) 2004-02-20 2005-08-25 Kucera Pharmaceutical Company Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses
HRP20130971T1 (hr) 2004-02-20 2013-11-08 Boehringer Ingelheim International Gmbh Inhibitori virusne polimeraze
KR20120039763A (ko) 2004-06-08 2012-04-25 버텍스 파마슈티칼스 인코포레이티드 약학 조성물
TWI437990B (zh) 2004-10-29 2014-05-21 Vertex Pharma Vx-950之醫藥用途
AU2007217355B2 (en) 2006-02-27 2012-06-21 Vertex Pharmaceuticals Incorporated Co-crystals comprising VX-950 and pharmaceutical compositions comprising the same
TWI428125B (zh) 2006-03-20 2014-03-01 Vertex Pharma 對包括vx-950之藥物實施噴霧乾燥之方法及由此方法製備之產物
US20070218138A1 (en) 2006-03-20 2007-09-20 Bittorf Kevin J Pharmaceutical Compositions
HRP20120330T1 (hr) 2007-02-27 2012-05-31 Vertex Pharmaceuticals Incorporated Sukristali i farmaceutski pripravci koji ih sadrže
CN101854936A (zh) * 2007-05-21 2010-10-06 弗特克斯药品有限公司 包含vx-950的剂型及其给药方案
WO2009061395A2 (en) * 2007-11-05 2009-05-14 Vertex Pharmaceuticals Incorporated Hcv combination therapies
WO2009131696A1 (en) * 2008-04-23 2009-10-29 Vertex Pharmaceuticals Incorporated Treatment of hepatitis c virus infections with telaprevir (vx-950) in patients non-responsive to treatment with pegylated interfer0n-alpha-2a/2b and ribavirin
JP2011522862A (ja) * 2008-06-10 2011-08-04 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ テラプレビル（Ｔｅｌａｐｒｅｖｉｒ）投薬養生法
EA201170484A1 (ru) * 2008-09-24 2012-03-30 Вертекс Фармасьютикалз Инкорпорейтед Терапевтический режим лечения гепатита, включающий пэг-интерферон, рибавирин и vx-950

Similar Documents

Publication Publication Date Title
JP2012517478A5 (https=)
JP2014530874A5 (https=)
JP2013518124A5 (https=)
JP2013533858A5 (https=)
JP2014530220A5 (https=)
JP2011519364A5 (https=)
JP2013155188A5 (https=)
HRP20170056T2 (hr) Terapija male učestalosti glatiramer acetatom
MX2012008652A (es) Terapias para tratar infeccion por virus de hepatitis c.
JP2012193216A5 (https=)
SI2709613T1 (en) Procedures for the treatment of HCV
HRP20170358T1 (hr) Inhibitori histonskih demetilaza
MD4430B1 (ro) Compoziţii şi metode de tratament al hepatitei virale C
JP2012529488A5 (https=)
NZ606993A (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
WO2008063727A3 (en) Combination therapy for treatment of viral infections
JP2011528333A5 (https=)
HK1198869A1 (en) Combination treatments for hepatitis c
JP2013541583A5 (https=)
NZ625592A (en) Compositions and methods for the treatment of hepatic diseases and disorders
RU2013148779A (ru) Лечение инфекции вируса гепатита в по отдельности или в комбинации с вирусом гепатита дельта и родственных заболеваний печени
HK1206246A1 (en) Use of high dose laquinimod for treating multiple sclerosis
JP2015532293A5 (ja) 糖尿病患者における心不全の治療用組成物
JP2012503669A5 (https=)
NZ598465A (en) Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin